Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation
Depression is a common mental disorder. Its treatment with selective serotonin reuptake inhibitors (SSRIs) is effective only in a fraction of patients, and pharmacoresistance is increasing steadily. Intranasal (IN) drug delivery to the brain stands out as a promising strategy to improve current ther...
Guardado en:
Autores principales: | Soraia Silva, Joana Bicker, Carla Fonseca, Nuno R. Ferreira, Carla Vitorino, Gilberto Alves, Amílcar Falcão, Ana Fortuna |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c555d32d8b50493e9adac2c1c0e8ed7d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression
por: Soraia Silva, et al.
Publicado: (2021) -
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017) -
Reversed phase HPLC determination of zidovudine in rat plasma and its pharmacokinetics after a single intranasal dose administration
por: MAINARDES,RUBIANA M, et al.
Publicado: (2009) -
Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival
por: Marija Kosić, et al.
Publicado: (2022) -
Paroxetine overdose during pregnancy
por: Selin Acar, et al.
Publicado: (2021)